The federal 340B drug pricing program has evolved from a modest drug discount program into a major part of the US healthcare system.
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing scrutiny, and antitrust litigation.
Archan Ruparel, CRA economist and Life Sciences Principal, was invited to discuss the economics behind the 340B program with Brian Auricchio and Jaclyn Phillips on Our Curious Amalgam.
The episode, titled “What’s 340B? An Economist’s View of the Recent Wave of 340B Litigation,” captures a discussion that explores:
- The impact of contract pharmacy expansion on the 340B ecosystem
- The economic drivers behind manufacturer restrictions and litigation
- How economists assess competition, market power, and antitrust claims in healthcare markets
Listen to the full episode, or watch below, and get answers to the antitrust questions emerging from the legal issues stemming from the 340B program.
